METHODS OF TRANSPLANTING CHONDROCYTES

• US 20150283303A1
• Filed: 10/29/2013
• Published: 10/08/2015
• Est. Priority Date: 10/29/2012
• Status: Active Grant

• Current Assignee: Scripps Health
• Original Assignee: Scripps Health
• Inventors: D'Lima, Darryl D., Olee, Tsaiwei, Colwell, Clifford W.
• Granted Patent: US 9,974,885 B2
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61L 2300/412 Tissue-regenerating or healing or proliferative agents
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: A61L 2430/06 for cartilage reconstruction, e.g. meniscus
• CPC Class Codes: A61L 27/26 Mixtures of macromolecular compounds
• CPC Class Codes: A61L 27/3817 Cartilage-forming cells, e.g. pre-chondrocytes
• CPC Class Codes: A61L 27/3821 Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
• CPC Class Codes: A61L 27/44 having a macromolecular matrix
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: C08L 5/08 Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
• CPC Class Codes: C08L 89/06 derived from leather or skin , e.g. gelatin

Abstract

Provided are tri-component matrices having collagen, hyaluronan, and chondroitin sulfate. Also provided are processes for producing a tri-component matrix. Additionally, provided are processes for providing cells capable of producing cartilage to a bone or cartilage defects.

Claims

1. A tri-component matrix comprising:

a) isolated and purified non-denatured type II collagen;

b) hyaluronan; and

c) chondroitin sulfate.

3. The tri-component matrix of claim 1, further comprising a basal media.

5. The tri-component matrix of claim 1, wherein the type II collagen is bovine-derived type II collagen.

6. The tri-component matrix of claim 1, wherein the concentration of type II collagen is from about 0.5 mg/ml to about 5 mg/ml.

7. The tri-component matrix of claim 1, wherein the concentration of type II collagen is about 3 mg/ml.

8. The tri-component matrix of claim 1, wherein the concentration of hyaluronan is from about 0.25 mg/ml to about 3 mg/ml.

9. The tri-component matrix of claim 1, wherein the concentration of hyaluronan is about 1 mg/ml.

10. The tri-component matrix of claim 1, wherein the concentration of chondroitin sulfate is from about 0.25 mg/ml to about 3 mg/ml.

11. The tri-component matrix of claim 1, wherein the concentration of chondroitin sulfate is about 1 mg/ml.

12. The tri-component matrix of claim 1, further comprising chondrocytes, chondroprogenitor cells, mesenchymal stem cells, induced pluripotent stem cells (iPS cells), iPS cells derived from chondrocytes, H9-derived chondroprogenitor cells, Sox-9 transduced chondrocytes, osteoblasts, osteoprogenitors, or any combinations thereof.

13. The tri-component matrix of claim 1, further comprising cells selected from chondrocytes, chondroprogenitor cells, and combination thereof.

15. The tri-component matrix of claim 1, further comprising iPS cells.

28. A method for inducing endogenous cartilage growth in a subject in need thereof, comprising implanting in the subject the tri-component matrix of claim 1.

29. A method of treating a bone or cartilage defect in a subject in need thereof, comprising administering a transplantation composition comprising:

i) a tri-component matrix, as claimed in claim 1, and ii) a population of cells, at the site of the bone or cartilage defect.

30. The method of claim 29, wherein the population of cells comprises chondrocytes, chondroprogenitor cells, iPS cells, mesenchymal stem cells, osteoblasts, osteoprogenitors, or combinations thereof.

37. The method of claim 29, wherein the population of cells comprises chondrocytes, chondroprogenitor cells, or a combination thereof.

44. The method of claim 29, wherein the subject has a cartilage-related disorder, wherein the cartilage-related disorder is selected from articular cartilage trauma, meniscus injury, a chonodrogenesis disorder, arthritis, chondropathy, chondrosarcoma, chondromalacia, polychondritis, relapsing polychondritis, slipped epiphysis, osteochondritis dissecans, chondrodysplasia, costochondritis, osteochondroma, spondylosis, osteochondroses, Tietze syndrome, dermochondrocorneal dystrophy of Francois, epiphyseal dysplasia, carpotarsal osteochondromatosis, achondropasia, chondrocalcinosis, genochondromatosis, chondroma, achondrogenesis, echondromata, hyprochondroplasia, and Keutel syndrome.

45. The method of claim 44, wherein the cartilage-related disorder is arthritis.

46. The method of claim 44, wherein the arthritis is osteoarthritis.

48. A cartilage repair implant comprising:

a) a tri-component matrix according to claim 1;

b) a population of cells; and

c) a biomaterial substrate, wherein the biomaterial substrate is selected from;

polyglycolic acid (PGA), polyactic acid, alginates, polyethylene oxide, fibrin adhesive, polylactic acid-polyglycolic acid copolymer, human dermis, a membrane such as a sheet, a porous body such as sponges, a mesh such as a knit, a textile, a non-woven fabric, cotton, porous material, and combinations thereof.

50. The cartilage repair implant of claim 48, wherein the population of cells is selected from chondrocytes, chondroprogenitor cells, mesenchymal stem cells, iPS cells, iPS cells derived from chondrocytes, H9-derived chondroprogenitor cells, Sox-9 transduced chondrocytes, osteoblasts, osteoprogenitors, and combinations thereof.

2. (canceled)

4. (canceled)

14. (canceled)

16-27. -27. (canceled)

31-36. -36. (canceled)

38-43. -43. (canceled)

47. (canceled)

49. (canceled)